Source Paper
Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice
Margaret Wong, Lee J. Martin
Human Molecular Genetics • 2010
View Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of motor neurons (MNs) that causes skeletal muscle paralysis. Familial forms of ALS are linked to mutations in the superoxide dismutase-1 (SOD1) gene. The mechanisms of human SOD1 (hSOD1) toxicity to MNs are unknown. We hypothesized that skeletal muscle is a primary site of pathogenesis in ALS that triggers MN degeneration. We created transgenic (tg) mice expressing wild-type-, G37R- and G93A-hSOD1 gene variants only in skeletal muscle. These tg mice developed age-related neurologic and pathologic phenotypes consistent with ALS. Affected mice showed limb weakness and paresis with motor deficits. Skeletal muscles developed severe pathology involving oxidative damage, protein nitration, myofiber cell death and marked neuromuscular junction (NMJ) abnormalities. Spinal MNs developed distal axonopathy and formed ubiquitinated inclusions and degenerated through an apoptotic-like pathway involving capsase-3. Mice expressing wild-type and mutant forms of hSOD1 developed MN pathology. These results demonstrate that human SOD1 in skeletal muscle has a causal role in ALS and identify a new non-autonomous mechanism for MN degeneration explaining their selective vulnerability. The discovery of instigating molecular toxicities or disease progression determinants within skeletal muscle could be very valuable for the development of new effective therapies for the treatment and cure of ALS.
Motor Function Assessment
Objective: Evaluation of motor deficits, limb weakness, and paresis in transgenic mice expressing SOD1 in skeletal muscle to assess motor neuron degeneration
This is a Motor Function Assessment protocol using mouse as the model organism. The procedure involves 1 procedural steps. Extracted from a 2010 paper published in Human Molecular Genetics.
Model and subjects
mouse • transgenic mice expressing wild-type-, G37R- and G93A-hSOD1 gene variants • unknown • age-related assessment • not specified
Study window
Estimated timing pending
Core workflow
Motor Function Assessment
Primary readouts
- Limb weakness
- Paresis
- Motor deficits
- Age-related neurologic phenotypes
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Motor Function Assessment
Evaluation of motor deficits, limb weakness, and paresis in transgenic mice expressing SOD1 in skeletal muscle
Note: Assessment was conducted on transgenic mice expressing wild-type-, G37R- and G93A-hSOD1 gene variants only in skeletal muscle. Affected mice showed limb weakness and paresis with motor deficits.
View evidence from paper
“Affected mice showed limb weakness and paresis with motor deficits. Skeletal muscles developed severe pathology involving oxidative damage, protein nitration, myofiber cell death and marked neuromuscular junction (NMJ) abnormalities.”